AI-driven initiative by SNMMI facilitates browsing of clinical trials
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has launched a new platform, the Global Radiopharmaceutical Trial Finder, designed to assist a wide range of users, including researchers, clinicians, and patients, in finding relevant radiopharmaceutical clinical trials.
Developed by Ancora.ai, this AI-powered platform uses real-time global trials data refreshed every 24 hours from ClinicalTrials.gov and three additional international registries. The Trial Finder is hosted on the SNMMI website and is accessible to all users.
To use the Trial Finder, users are guided through specific questions about disease stage, prior treatment, and other key factors. Each result in the Trial Finder includes the strength of the match to the trial criteria. The Trial Finder does not store or sell personal information, ensuring user privacy and security.
The Trial Finder is updated with new data every 24 hours, ensuring that users have access to the most recent trials. One of the standout features of the Trial Finder is its ability to provide the distance of the trial site from an entered location, making it easier for users to find trials in their area.
The results returned by the Trial Finder are a tailored list of trials for which patients may be eligible or trials that researchers may be interested in monitoring. The Trial Finder is intended to help users find radiopharmaceutical clinical trials that meet their specific needs.
In conclusion, the Global Radiopharmaceutical Trial Finder is a valuable resource for anyone seeking to participate in or monitor radiopharmaceutical clinical trials. With its AI-powered capabilities, real-time data updates, and user-friendly interface, the Trial Finder is set to revolutionise the way clinical trials are found and accessed.
